Certara (NASDAQ:CERT) Issues FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 0.350-0.410 for the period, compared to the consensus earnings per share estimate of 0.420. The company issued revenue guidance of $395.0 million-$405.0 million, compared to the consensus revenue estimate of $426.1 million.

Certara Price Performance

Shares of NASDAQ:CERT opened at $6.31 on Monday. The stock has a market capitalization of $967.45 million, a P/E ratio of -631.00 and a beta of 1.53. The business has a 50-day moving average of $6.25 and a two-hundred day moving average of $8.11. Certara has a fifty-two week low of $5.19 and a fifty-two week high of $13.88. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The company had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. During the same period in the prior year, the company posted $0.15 EPS. The business’s revenue was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts predict that Certara will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CERT. Leerink Partners restated an “outperform” rating and issued a $10.00 price objective on shares of Certara in a research note on Thursday, February 26th. Craig Hallum lowered shares of Certara from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a research note on Friday, February 27th. KeyCorp dropped their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, April 13th. Wall Street Zen lowered shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. Finally, Barclays restated an “equal weight” rating and set a $8.00 price target on shares of Certara in a report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.44.

Institutional Trading of Certara

A number of hedge funds have recently bought and sold shares of CERT. Corient Private Wealth LLC increased its holdings in shares of Certara by 11.7% during the 2nd quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock worth $144,000 after purchasing an additional 1,295 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Certara by 5,083.8% in the third quarter. Russell Investments Group Ltd. now owns 10,886 shares of the company’s stock valued at $133,000 after buying an additional 10,676 shares during the period. WINTON GROUP Ltd bought a new stake in shares of Certara in the fourth quarter valued at about $128,000. Persistent Asset Partners Ltd acquired a new stake in Certara during the fourth quarter worth about $113,000. Finally, Bridgefront Capital LLC acquired a new stake in Certara during the fourth quarter worth about $103,000. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.